The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BMY | +13.41% | +24.09% | +4.41% | +20,426% |
| S&P | +13.95% | +78.35% | +12.25% | +7,113% |
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $12.50B | 0.0% |
| Gross Profit | $8.98B | 0.0% |
| Gross Margin | 71.84% | 0.0% |
| Market Cap | $109.81B | 0.0% |
| Market Cap / Employee | $3.22M | 0.0% |
| Employees | 34.1K | 0.0% |
| Net Income | $1.09B | 0.0% |
| EBITDA | $4.87B | 0.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.21B | 0.0% |
| Accounts Receivable | $9.85B | 1.4% |
| Inventory | 2.8K | -17.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $42.85B | 0.0% |
| Short Term Debt | $2.26B | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.34% | 14.2% |
| Return On Invested Capital | 1.27% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $5.99B | 13.7% |
| Operating Free Cash Flow | $6.31B | 12.9% |
| Metric | Q2 2025 | Q3 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 18.68 | 16.35 | 15.23 | 15.60 | -31.89% |
| Price to Book | 5.42 | 5.05 | 5.26 | 5.92 | -21.86% |
| Price to Sales | 1.98 | 2.06 | 1.91 | 2.28 | -12.54% |
| Price to Tangible Book Value | -3.51 | -3.43 | -3.57 | -4.64 | 7.63% |
| Price to Free Cash Flow TTM | 12.69 | 15.22 | 9.80 | 8.93 | -23.56% |
| Enterprise Value to EBITDA | 29.93 | 28.85 | 24.59 | 29.67 | -12.15% |
| Free Cash Flow Yield | 7.9% | 6.6% | 10.2% | 11.2% | 30.82% |
| Return on Equity | -39.1% | 32.0% | 29.3% | 33.8% | -207.55% |
| Total Debt | $50.93B | $48.98B | $51.04B | $45.11B | -11.96% |
These stocks skyrocketed following exciting announcements.
Carl Icahn's reportedly focusing his brand of investor activism on Bristol-Myers Squibb, but it's anyone's guess if he'll be able to convince the company to sell. Also, Celgene delivers a phase 3 win with blockbuster implications.
In this Valentine's Day edition, Industry Focus explores cholesterol busters, heart surgery, and the latest in anticoagulants.
From a big-time patent settlement between Merck & Co. and Bristol-Myers Squibb, to Johnson & Johnson's earnings, to Aetna and Humana's $37 billion merger bust, we dive into the details behind last week's biggest healthcare stories.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
